

Real-time national survey of COVID-19 in hemoglobinopathy patients

Haematologica

105, 2651-2654

DOI: [10.3324/haematol.2020.259440](https://doi.org/10.3324/haematol.2020.259440)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Fat Embolism Syndrome in Sickle Cell Disease. <i>Journal of Clinical Medicine</i> , 2020, 9, 3601.	1.0	35
2	SARS-CoV-2-associated coagulopathy and thromboembolism prophylaxis in children: A single-center observational study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 522-530.	1.9	50
3	Incidence Rate of COVID-19 Infection in Hemoglobinopathies: A Systematic Review and Meta-analysis. <i>Hemoglobin</i> , 2021, 45, 371-379.	0.4	12
4	COVID-19 outcomes in a large pediatric hematology-oncology center in Houston, Texas. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 695-706.	0.3	18
5	How we approach thrombosis risk in children with COVID-19 infection and MIS. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29049.	0.8	25
6	A case of ischemic colitis in a patient with non transfusion dependent thalassemia (NTDT) infected by SARS-CoV-2. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 1-8.	0.3	0
7	Sickle cell disease and COVID-19: Susceptibility and severity. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29075.	0.8	25
9	Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. <i>Blood Advances</i> , 2021, 5, 2717-2724.	2.5	47
11	SARS-CoV-2 infection in patients with β^0 -thalassemia: The French experience. <i>Transfusion Clinique Et Biologique</i> , 2022, 29, 70-74.	0.2	5
12	Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York. <i>Haematologica</i> , 2021, 106, 3014-3016.	1.7	32
13	COVID-19 Infection in Sickle Cell Patients in a Developing Country: A Case Series. <i>Acta Haematologica</i> , 2022, 145, 1-4.	0.7	3
14	The real impact of COVID-19 on an East London Sickle cell population: results of a service-wide survey. <i>British Journal of Haematology</i> , 2021, 195, 532-535.	1.2	3
15	Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 629-634.	0.6	55
16	COVID-19 and sickle cell disease. <i>Haematologica</i> , 2020, 105, 2501-2504.	1.7	30
17	Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. <i>Frontiers in Medicine</i> , 2021, 8, 679030.	1.2	0
18	Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature. <i>Blood Reviews</i> , 2022, 53, 100911.	2.8	28
19	Immunogenicity of The BNT162b2 COVID-19 mRNA and ChAdOx1 nCoV-19 Vaccines in Patients with Hemoglobinopathies. <i>Vaccines</i> , 2022, 10, 151.	2.1	6
20	From H1N1 to COVID-19: What we have seen in children with hemoglobinopathies. <i>Clinics</i> , 2022, 77, 100004.	0.6	1

#	ARTICLE	IF	CITATIONS
21	Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis. <i>EClinicalMedicine</i> , 2022, 44, 101287.	3.2	77
22	Favorable outcomes of patients with sickle cell disease hospitalized due to COVID-19: A report of three cases. <i>Experimental and Therapeutic Medicine</i> , 2022, 23, 338.	0.8	3
23	Thalassemia and COVID-19: Susceptibility and Severity. <i>Iranian Journal of Pediatrics</i> , 2021, 31, .	0.1	3
24	Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	19
25	Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. <i>Frontiers in Medicine</i> , 2021, 8, 679030.	1.2	4
26	Sickle cell disease patients with COVID-19 in Guadeloupe: Surprisingly favorable outcomes. <i>EJHaem</i> , 2022, 3, 636-643.	0.4	4
27	Determinants of severity in sickle cell disease. <i>Blood Reviews</i> , 2022, 56, 100983.	2.8	13
28	Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101375.	0.7	0
29	Haematology audit of 801 COVID-19 patients' basics and beyond- Prospective observational study. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4460.	0.3	1
30	SARS-CoV-2 Infection Presenting as Acute Chest Syndrome in a Child With Hemoglobin SD-Los Angeles Disease: A Case Report and Review of Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 0, Publish Ahead of Print, .	0.3	0
31	COVID-19 vaccination status and disease burden in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2022, 199, .	1.2	4
42	Effects of Beta-Thalassemia on COVID-19 Outcomes. , 0, , .		0